At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 202 enrolled
Drug / intervention
Ranibizumabdrug
Likely dose
Ranibizumab 10 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicenter Randomized Study Evaluating Dosing Regimens for Treatment With Intravitreal Ranibizumab Injections in Subjects With Macular Edema Following Retinal Vein Occlusion
In Brief
A Phase 4 clinical trial evaluating Ranibizumab for Macular Edema. Completed, enrolled 202 participants across 42 sites.
Detailed Summary
This was a Phase IV multicenter, randomized, open-label study, with masking of the vision examiner, of the efficacy and safety of intravitreal ranibizumab 0.5 mg in subjects with macular edema following Branch Retinal Vein Occlusion (BRVO) or Central Retinal Vein Occlusion (CRVO).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMacular Edema
CountriesUnited States
Collaborators--
Timeline
Phase 4CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedJan 2011
Enrollment StartFeb 2011
Primary CompletionOct 2012
TodayJul 2026
First PostedJan 14, 2011
Enrollment StartFeb 1, 2011
Primary CompletionOct 1, 2012
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 15.5 years ago
Interventions
Ranibizumabdrug
Liquid ranibizumab (10 mg/ml) was supplied in a sterile solution in single-use vials.